3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
6
Phase 2
4
Phase NA
1
Phase EARLY_PHASE1
1
Phase 1/2
1
Status
Unknown
2
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Neoplasms
1
Melanoma
1
Interventions
Cyclophosphamide
142
Gemcitabine
129
Paclitaxel
125
Radiotherapy
119
Carboplatin
112
Cisplatin
111
pembrolizumab
110
Nivolumab
106
Docetaxel
90
Rituximab
86
Lenalidomide
77
Dexamethasone
76
Cytarabine
69
Bevacizumab
64
Fluorouracil
63
Etoposide
63
Oxaliplatin
62
Filgrastim
59
Peripheral Blood Stem Cell Transplantation
58
Everolimus
58
Capecitabine
58
fludarabine phosphate
57
Doxorubicin
56
Temozolomide
55
Prednisone
54
Irinotecan
53
Cetuximab
50
fludarabine
48
Ipilimumab
48
Erlotinib Hydrochloride
48
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Completed
×
Protein Subunit Vaccines
×
Clear all
NCT02126579
2024-02-28
MEL60
University of Virginia
Phase 1/2
Completed
50 enrolled
13 charts